DK0981327T3 - Intravaginale lægemiddeltilførselsanordninger til indgivelse af testosteron og testosteronprecursorer - Google Patents

Intravaginale lægemiddeltilførselsanordninger til indgivelse af testosteron og testosteronprecursorer

Info

Publication number
DK0981327T3
DK0981327T3 DK98921701T DK98921701T DK0981327T3 DK 0981327 T3 DK0981327 T3 DK 0981327T3 DK 98921701 T DK98921701 T DK 98921701T DK 98921701 T DK98921701 T DK 98921701T DK 0981327 T3 DK0981327 T3 DK 0981327T3
Authority
DK
Denmark
Prior art keywords
testosterone
administration
drug delivery
delivery devices
precursors
Prior art date
Application number
DK98921701T
Other languages
Danish (da)
English (en)
Inventor
Clare Passmore
Claire Gilligan
Original Assignee
Galen Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galen Chemicals Ltd filed Critical Galen Chemicals Ltd
Application granted granted Critical
Publication of DK0981327T3 publication Critical patent/DK0981327T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98921701T 1997-05-07 1998-05-07 Intravaginale lægemiddeltilførselsanordninger til indgivelse af testosteron og testosteronprecursorer DK0981327T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE970333 1997-05-07
PCT/IE1998/000033 WO1998050016A2 (en) 1997-05-07 1998-05-07 Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Publications (1)

Publication Number Publication Date
DK0981327T3 true DK0981327T3 (da) 2003-03-10

Family

ID=11041465

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98921701T DK0981327T3 (da) 1997-05-07 1998-05-07 Intravaginale lægemiddeltilførselsanordninger til indgivelse af testosteron og testosteronprecursorer

Country Status (15)

Country Link
US (1) US6416780B1 (es)
EP (1) EP0981327B1 (es)
JP (1) JP2001524124A (es)
CN (1) CN1184957C (es)
AT (1) ATE227120T1 (es)
AU (1) AU741482B2 (es)
CA (1) CA2288046C (es)
DE (1) DE69809222T2 (es)
DK (1) DK0981327T3 (es)
ES (1) ES2187024T3 (es)
IL (1) IL132702A0 (es)
NO (1) NO995419L (es)
NZ (1) NZ501236A (es)
PT (1) PT981327E (es)
WO (1) WO1998050016A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2003080018A1 (en) * 2002-03-27 2003-10-02 Galen (Chemicals) Limited Intravaginal matrix drug delivery devices
US8399013B2 (en) 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
US8404272B2 (en) 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
WO2007021964A2 (en) 2005-08-11 2007-02-22 Massachusetts Institute Of Technology Intravesical drug delivery device and method
WO2007115261A2 (en) * 2006-03-31 2007-10-11 Qlt Plug Delivery, Inc. Drug delivery methods, structures, and compositions for nasolacrimal system
TW200833695A (en) 2006-10-12 2008-08-16 Xenon Pharmaceuticals Inc Use of spiro-oxindole compounds as therapeutic agents
WO2009076547A2 (en) 2007-12-11 2009-06-18 Massachusetts Institute Of Technology Implantable drug delivery device ant) methods for treatment of the bladder and other body vestcles or lumens
LT2249757T (lt) * 2008-02-04 2017-09-25 Ferring B.V. Vientisi intravaginaliniai žiedai, apimantys progesteroną, ir jų gamybos bei panaudojimo būdai
US9034365B2 (en) 2008-05-20 2015-05-19 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
JP5908279B2 (ja) * 2008-08-09 2016-04-26 マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ 移植可能な薬物送達デバイス並びに男性の尿生殖器及び周囲組織を治療する方法
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN103664973B (zh) 2008-10-17 2017-04-19 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
CA2947339A1 (en) 2009-06-26 2010-12-29 Heejin Lee Implantable drug delivery devices and methods of making the same
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
NZ712378A (en) 2009-10-14 2017-05-26 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
SG183126A1 (en) 2010-02-26 2012-09-27 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
RU2620032C2 (ru) 2011-01-10 2017-05-22 Аллерган, Инк. Схема приема лидокаина для применения в продолжительном лечении боли в мочевом пузыре и раздражения при мочеиспускании
KR20140048086A (ko) 2011-02-04 2014-04-23 타리스 바이오메디컬 인코포레이티드 저 용해성 약물의 제어 방출을 위한 이식가능한 디바이스
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP3290024B1 (en) 2011-08-29 2019-04-17 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP6014154B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
SG10201708522SA (en) 2013-03-15 2017-12-28 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
CA2904444A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Dual reactivity potent kunitz inhibitor of fibrinolysis
EP3035991B1 (en) 2013-08-19 2020-07-08 TARIS Biomedical LLC Multi-unit drug delivery devices
CN104546668B (zh) * 2013-10-23 2019-03-05 国家卫生计生委科学技术研究所 液体硅橡胶为载体的药物缓控释系统的制备及应用
US9820994B2 (en) * 2014-06-28 2017-11-21 Laboratorios Andromaco S.A. Cerclage pessary containing progesterone of prolonged, sustained, and continuous release useful for prevention of preterm birth
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US10894150B2 (en) 2015-04-23 2021-01-19 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
AU2017220738B2 (en) 2016-02-19 2022-02-24 Phoenix Molecular Designs Carboxamide derivatives useful as RSK inhibitors
MX2018013985A (es) 2016-05-20 2019-08-22 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos.
CA3042004A1 (en) 2016-12-09 2018-06-14 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2019241533A1 (en) 2018-06-13 2019-12-19 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
PE20211065A1 (es) 2018-07-27 2021-06-09 Xenon Pharmaceuticals Inc Metodo para tratar la epilepsia
WO2020047312A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
EA202190395A1 (ru) 2018-08-31 2021-06-15 Ксенон Фармасьютикалз Инк. Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств
US11813354B1 (en) 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
KR20210126077A (ko) 2019-02-11 2021-10-19 피닉스 몰레큘라 디자인스 Rsk 억제제의 결정형
KR20240070604A (ko) 2021-09-24 2024-05-21 제논 파마슈티칼스 인크. 소듐 채널 활성화제로서 피리디닐아세트아미드 유도체
US20230144095A1 (en) 2021-09-24 2023-05-11 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
IL311056A (en) 2021-09-24 2024-04-01 Xenon Pharmaceuticals Inc Pyridine derivatives as sodium channel activators
TW202404583A (zh) 2022-06-08 2024-02-01 加拿大商再諾製藥公司 吡啶胺衍生物及其作為鉀通道調節劑之用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920805A (en) * 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
GB2079158B (en) * 1980-06-09 1985-01-09 Ahi Operations Ltd Intra-vaginal devices
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
IL116433A (en) * 1994-12-19 2002-02-10 Galen Chemicals Ltd INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS

Also Published As

Publication number Publication date
EP0981327A2 (en) 2000-03-01
CA2288046C (en) 2006-10-03
CN1184957C (zh) 2005-01-19
CA2288046A1 (en) 1998-11-12
AU741482B2 (en) 2001-11-29
WO1998050016A2 (en) 1998-11-12
ATE227120T1 (de) 2002-11-15
NO995419L (no) 2000-01-07
WO1998050016A3 (en) 1999-02-04
US6416780B1 (en) 2002-07-09
NO995419D0 (no) 1999-11-05
ES2187024T3 (es) 2003-05-16
DE69809222D1 (de) 2002-12-12
EP0981327B1 (en) 2002-11-06
NZ501236A (en) 2002-02-01
JP2001524124A (ja) 2001-11-27
DE69809222T2 (de) 2003-08-14
IL132702A0 (en) 2001-03-19
AU7446998A (en) 1998-11-27
CN1255056A (zh) 2000-05-31
PT981327E (pt) 2003-02-28

Similar Documents

Publication Publication Date Title
DK0981327T3 (da) Intravaginale lægemiddeltilførselsanordninger til indgivelse af testosteron og testosteronprecursorer
AU1227899A (en) Osmotic medicament releasing system
GB2341550A (en) Gastroretentive controlled release microspheres for improved drug delivery
ID21259A (id) Sistim penyaluran obat untuk dua atau lebih bahan-bahan aktif
WO2003077972A8 (en) Implantable drug delivery system
WO2003028660A3 (en) Drug delivery devices and methods
DK0841903T3 (da) Orale farmaceutiske præparater indeholdende antimikrobielt virksomme aktivstoffer og sustained release pantoprazol
DK0799025T3 (da) Intravaginale stoftilførselsanordninger til tilførsel af 17beta-østradiolprækursorer
NO20016108L (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
ES2180574T3 (es) Formulaciones de liberacion controlada de oxibutinina.
WO2002076426A3 (en) Intravaginal drug delivery devices for the administration of an antimicrobial agent
GB2338414A (en) Intravesical drug delivery system
BR0215262A (pt) Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas
WO2002053128A3 (en) Sustained release drug delivery devices with multiple agents
CA2292402A1 (en) Intra-vaginal device for pigs
EP1499300A4 (en) PHARMACEUTICAL FORMULATIONS WITH IMPROVED BIOAVAILABILITY
HK1032010A1 (en) Medicament formulation with a controlled release of an active agent.
HK1043049A1 (en) Core tablet for controlled release of gliclazide after oral administration.
WO1998026767A3 (en) Site-specific controlled release dosage formulation for mesalamine
NO307813B1 (no) Farmasøytisk og galenisk preparatform
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
HK1060691A1 (en) Ion-strength independent sustained release pharmaceutical formulation
WO2002036077A3 (en) Once a day antihistamine and decongestant formulation
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases